Dupilumab in Severe Asthma: Two Years of Real-World Evidence

Severe asthma remains challenging to manage, particularly in patients experiencing persistent symptoms and exacerbations despite optimised treatment. Increasingly, therapeutic goals extend beyond symptom control towards achieving clinical remission.

Dupilumab, a monoclonal antibody targeting the shared receptor component of interleukin (IL)-4 and IL-13, inhibits key pathways involved in type 2 inflammation. Although randomised controlled trials have demonstrated its efficacy in severe asthma, evidence of sustained effectiveness in routine clinical practice remains limited.